



MAVDA Newsletter

21 June 2024 | Issue 5



As we embark on the third and final year of our drug accelerator program, it's an opportune moment to reflect on the significant strides we've made together as a consortium. Our Annual Research Performance Progress Report (RPPR) submitted to the NIH underscores our substantial progress in advancing the next generation of antiviral therapies.

It is imperative that we leverage our achievements and maintain our focus on advancing preclinical antiviral drug candidates. Our collective effort is crucial in ensuring the sustained success of MAVDA, as we aim to secure future external funding to sustain our projects and core activities.



Recent Updates



Upcoming NIH Quarterly Meeting

Quarterly report (2-3 PPT slides) to NIH-NIAID is due on the 26th July 2024 (Friday). Email with details and template will be shared shortly.


[Important Dates](#)

Publications & Patents

Visit our website for latest publications and patents from MAVDA members.

Note: Please ensure all patents and inventions are reported via iEdison for compliance with NIH-NIAID guidelines.

[Publications/Patents List](#)



AviDD Centers-Resource Sharing

NIAID offers the BEI Resources Repository for sharing novel biological reagents (reporter viruses, minigenomes, cell lines, etc) developed by the AviDD centers with the broader research community. We are consolidating a list of potential reagents from MAVDA for initial review by DMID, aiming for submission by December 31, 2024, to facilitate resource sharing and advance scientific collaboration. Reach out to Madhu if you have a resource you want to add to the BEI repository.